WebOptherion, Inc., a biotechnology company, develops diagnostic and disease-modifying therapeutics for the management and treatment of WebOct 9, 2007 · Optherion, Inc.— a company that will use groundbreaking discoveries by scientists at Yale and the University of Iowa to develop products to diagnose and treat …
Optherion - Funding, Financials, Valuation & Investors - CrunchBase
WebJul 1, 2009 · Spurred by the commercial success of Lucentis, start-ups developing new therapeutics for AMD tap into a growing understanding of the pathogenesis of the disease. In this issue, we profile five emerging AMD drug developers: Acucela, Iconic Therapeutics, MacuCLEAR, Ophthotech, Optherion and Sirion Therapeutics. WebJan 1, 2008 · Optherion Obtains Funding for AMD Research First Focus Is on Dry AMD. Optherion, Inc., a recently formed company that intends to develop diagnostic tools and treatments for both the wet and dry forms of AMD, says it will first focus on developing diagnostic tests and disease-modifying therapies to prevent loss of vision in patients with … the peninsula neighborhood iowa city
Sequenom Licenses Rights to Macular Degeneration Genetic Test
WebOptherion. Optherion, Inc. is an early-stage biotechnology company that is developing products to treat and diagnose dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system. Optherion's technologies are based on scientific discoveries linking certain genes to AMD. WebOptherion has not claimed their Profile. Want to better differentiate Optherion between your competitors? Show buyers how. O. Why does Optherion win vs. Axxam? Show Optherion's primary competitive advantage. Show Optherion's competitive differentiation. Work for Optherion? Share why your customers love you. WebOct 9, 2007 · NEW HAVEN, Conn., Oct. 9 /PRNewswire/ -- Optherion, Inc., a company developing products to diagnose and treat dry and wet Age-related Macular Degeneration … the peninsula new york reviews